There are currently 1307 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Healthcare of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Red Blood Cell Survival in Sickle Cell Disease
NCT04426591
Recruiting
This is a single-arm, mechanistic clinical trial to measure predictors of senescence and the in vivo survival of transfused red blood cells (RBCs) in individuals with sickle cell disease (SCD) receiving chronic transfusion therapy (CTT). Chronic transfusion in patients with SCD is a common treatment. The efficacy of RBC transfusion therapy to treat or prevent complications of SCD may be hampered by variable survival of the transfused donor RBC. The overall aim is to see how long RBC survive in S... Read More
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
12/20/2024
Locations: Hughes Spalding Children's Hospital, Atlanta, Georgia +2 locations
Conditions: Sickle Cell Disease
Register for Updates
Bioenergetic Effect of Pioglitazone in CLD-PH
NCT06336798
Recruiting
The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD. Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Emory Healthcare System, Atlanta, Georgia
Conditions: Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
Register for Updates
The ENCIRCLE Trial
NCT04153292
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Emory University, Atlanta, Georgia +1 locations
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Register for Updates
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
NCT05696717
Recruiting
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/20/2024
Locations: Theravance Biopharma Investigative Site, Atlanta, Georgia
Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Register for Updates
Testing an Integrated Care Model Trial
NCT06448429
Recruiting
This study aims to test the use of an adapted collaborative care model for improving the health outcomes of adults diagnosed with type 1 diabetes (T1D). The duration of the study is 18 months with 4 study survey points. Participants will fill out an online survey regarding their psychosocial health and chronic disease management behaviors once every six months over the 18 months, and individuals who are randomly assigned to the study intervention will also consult at least once with a behavioral... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Grady Health System, Atlanta, Georgia
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749
Recruiting
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
12/19/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Systemic Lupus Erythematosus
Register for Updates
Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab (pembro) in Patients with Selected Advanced or Metastatic Solid Tumors
NCT05479812
Recruiting
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Emory Winship Cancer Institute, Atlanta, Georgia
Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Register for Updates
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
NCT03493425
Recruiting
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Emory Proton Therapy Center, Atlanta, Georgia +2 locations
Conditions: Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
Register for Updates
Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
NCT04801771
Recruiting
This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and t... Read More
Gender:
ALL
Ages:
Between 10 years and 21 years
Trial Updated:
12/19/2024
Locations: Children's Healthcare of Atlanta/ Emory University School of Medicine, Atlanta, Georgia
Conditions: Down Syndrome, Obstructive Sleep Apnea
Register for Updates
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Recruiting
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Multiple Myeloma
Register for Updates
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
NCT06328608
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
12/18/2024
Locations: Emory Genetics Clinical Trials Center, Atlanta, Georgia
Conditions: Fabry Disease
Register for Updates
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560
Recruiting
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Lymphangioleiomyomatosis
Register for Updates